Log in

Relevant bibliographies by topics / Electrochemiluminescent analysis / Journal articles

Journal articles on the topic 'Electrochemiluminescent analysis'

To see the other types of publications on this topic, follow the link: Electrochemiluminescent analysis.

Author: Grafiati

Published: 30 May 2022

Last updated: 31 May 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Electrochemiluminescent analysis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

JIANG, Hui, and Xue-Mei WANG. "Progress of Metal Nanoclusters-based Electrochemiluminescent Analysis." Chinese Journal of Analytical Chemistry 45, no. 12 (December 2017): 1776–85. http://dx.doi.org/10.1016/s1872-2040(17)61054-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Sun, Yu-Gang, Hua Cui, Xiang-Qin Lin, Ying-Hui Li, and Hua-Zhang Zhao. "Flow injection analysis of pyrogallol with enhanced electrochemiluminescent detection." Analytica Chimica Acta 423, no. 2 (November 2000): 247–53. http://dx.doi.org/10.1016/s0003-2670(00)01121-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Xu, Huifeng, Xi Zhu, Jian Wang, Zhenyu Lin, and Guonan Chen. "Electrochemiluminescent functional nucleic acids‐based sensors for food analysis." Luminescence 34, no. 3 (January 28, 2019): 308–15. http://dx.doi.org/10.1002/bio.3596.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ma, Xiangui, Liming Qi, Wenyue Gao, Fan Yuan, Yong Xia, Baohua Lou, and Guobao Xu. "A portable wireless single-electrode system for electrochemiluminescent analysis." Electrochimica Acta 308 (June 2019): 20–24. http://dx.doi.org/10.1016/j.electacta.2019.04.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Salehnia, Foad, Morteza Hosseini, and Mohammad Reza Ganjali. "Enhanced electrochemiluminescence of luminol by an in situ silver nanoparticle-decorated graphene dot for glucose analysis." Analytical Methods 10, no. 5 (2018): 508–14. http://dx.doi.org/10.1039/c7ay02375h.

Full text

Abstract:

Herein, a rapid, linker-free, single-step strategy for in situ synthesis of graphene quantum dot–luminol–Ag nanoparticle (GQD–luminol–AgNP) nanocomposites was designed by reducing AgNO₃ with an electrochemiluminescent reagent, luminol, in the presence of GQDs.

APA, Harvard, Vancouver, ISO, and other styles

6

Cao, Jun-Tao, Xiao-Long Fu, Fu-Rao Liu, Shu-Wei Ren, and Yan-Ming Liu. "Reduced graphene oxide-gold nanoparticles-catalase-based dual signal amplification strategy in a spatial-resolved ratiometric electrochemiluminescence immunoassay." Analyst 145, no. 1 (2020): 91–96. http://dx.doi.org/10.1039/c9an02056j.

Full text

Abstract:

A novel spatial-resolved electrochemiluminescent (ECL) ratiometry for cardiac troponin I (cTnI) analysis was developed using resonance energy transfer (RET) and a coreactant consumption strategy for signal amplification.

APA, Harvard, Vancouver, ISO, and other styles

7

Sun, Yu-Gang, Hua Cui, Ying-Hui Li, Hua-Zhang Zhao, and Xiang-Qin Lin. "Flow Injection Analysis of Tannic Acid with Inhibited Electrochemiluminescent Detection." Analytical Letters 33, no. 11 (January 2000): 2281–91. http://dx.doi.org/10.1080/00032710008543189.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

FU, ZhiFeng. "Electrochemiluminescent immunosensing and its application in biological and pharmaceutical analysis." Scientia Sinica Chimica 41, no. 5 (2011): 773. http://dx.doi.org/10.1360/032010-682.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

ZHU, Liande, Yingxiu LI, and Guoyi ZHU. "Electrochemiluminescent Determination of L-Cysteine with a Flow-Injection Analysis System." Analytical Sciences 19, no. 4 (2003): 575–78. http://dx.doi.org/10.2116/analsci.19.575.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Forster, Robert J., and Conor F. Hogan. "Electrochemiluminescent Metallopolymer Coatings: Combined Light and Current Detection in Flow Injection Analysis." Analytical Chemistry 72, no. 22 (November 2000): 5576–82. http://dx.doi.org/10.1021/ac000605d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

AN Xiao-gang, 安晓刚, 杜. 捷. DU Jie, and 卢小泉 LU Xiao-quan. "Application in Life Analysis of Electrochemiluminescent Sensor Based on Noble Metal Nanocluster." Chinese Journal of Luminescence 38, no. 5 (2017): 675–84. http://dx.doi.org/10.3788/fgxb20173805.0675.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Yuan, Yali, Haijuan Li, Shuang Han, Lianzhe Hu, Saima Parveen, Haoran Cai, and Guobao Xu. "Immobilization of tris(1,10-phenanthroline)ruthenium with graphene oxide for electrochemiluminescent analysis." Analytica Chimica Acta 720 (March 2012): 38–42. http://dx.doi.org/10.1016/j.aca.2012.01.023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Liu, Gen, Pei-Long Wang, and Hui Gao. "Visualization analysis of lecithin in drugs based on electrochemiluminescent single gold microbeads." Journal of Pharmaceutical Analysis 11, no. 4 (August 2021): 515–22. http://dx.doi.org/10.1016/j.jpha.2021.02.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Brandon, David L., Anna M. Korn, and Lily L. Yang. "Immunosorbent analysis of ricin contamination in milk using colorimetric, chemiluminescent and electrochemiluminescent detection." Food and Agricultural Immunology 25, no. 2 (January 9, 2013): 160–72. http://dx.doi.org/10.1080/09540105.2012.753515.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Heroux, J. A., and A. M. Szczepanik. "Quantitative analysis of specific mRNA transcripts using a competitive PCR assay with electrochemiluminescent detection." Genome Research 4, no. 6 (June 1, 1995): 327–30. http://dx.doi.org/10.1101/gr.4.6.327.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Wei, Xiuhua, Changbin Xiao, Ke Wang, and Yifeng Tu. "A nano-TiO2 supported AuAg alloy nanocluster functionalized electrode for sensitizing the electrochemiluminescent analysis." Journal of Electroanalytical Chemistry 702 (August 2013): 37–44. http://dx.doi.org/10.1016/j.jelechem.2013.05.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Liu, Haiyun, Lina Zhang, Meng Li, Mei Yan, Mei Xue, Yan Zhang, Min Su, Jinghua Yu, and Shenguang Ge. "Electrochemiluminescent molecular logic gates based on MCNTs for the multiplexed analysis of mercury(ii) and silver(i) ions." RSC Advances 6, no. 31 (2016): 26147–54. http://dx.doi.org/10.1039/c6ra02531e.

Full text

Abstract:

In this paper, logic gates with electrochemiluminescence (ECL) signal as outputs were constructed based on the use of the thymine (T)-rich (S₁) or cytosine (C)-rich (S₂) oligonucleotides for the selective analysis of mercury ions (Hg²⁺) or silver ions (Ag⁺).

APA, Harvard, Vancouver, ISO, and other styles

18

Liang, Wenbin, Chenchen Fan, Ying Zhuo, Yingning Zheng, Chengyi Xiong, Yaqin Chai, and Ruo Yuan. "Multiparameter Analysis-Based Electrochemiluminescent Assay for Simultaneous Detection of Multiple Biomarker Proteins on a Single Interface." Analytical Chemistry 88, no. 9 (April 21, 2016): 4940–48. http://dx.doi.org/10.1021/acs.analchem.6b00878.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Lin, Meng Shan, Jun Sheng Wang, and Chien Hung Lai. "Electrochemiluminescent determination of nicotine based on tri(2,2′-bipyridyl) ruthenium (II) complex through flow injection analysis." Electrochimica Acta 53, no. 26 (November 2008): 7775–80. http://dx.doi.org/10.1016/j.electacta.2008.05.057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Han, En, Lin Ding, Shi Jin, and Huangxian Ju. "Electrochemiluminescent biosensing of carbohydrate-functionalized CdS nanocomposites for in situ label-free analysis of cell surface carbohydrate." Biosensors and Bioelectronics 26, no. 5 (January 2011): 2500–2505. http://dx.doi.org/10.1016/j.bios.2010.10.044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Kenten, J. H., J. Casadei, J. Link, S. Lupold, J. Willey, M. Powell, A. Rees, and R. Massey. "Rapid electrochemiluminescence assays of polymerase chain reaction products." Clinical Chemistry 37, no. 9 (September 1, 1991): 1626–32. http://dx.doi.org/10.1093/clinchem/37.9.1626.

Full text

Abstract:

Abstract We demonstrate the first use of an electrochemiluminescent (ECL) label, [4-(N-succimidyloxycarbonylpropyl)-4'-methyl-2,2'- bipyridine]ruthenium(II) dihexafluorophosphate (Origen label; IGEN Inc.), in DNA probe assays. This label allows rapid (less than 25 min) quantification and detection of polymerase chain reaction (PCR)-amplified products from oncogenes, viruses, and cloned genes. For the PCR, we used labeled oligonucleotide primers complementary to human papiloma virus and the Ha-ras oncogene. These samples were followed by ECL analysis or hybridization with specific, Origen-labeled oligonucleotide probes. These studies demonstrate the speed, specificity, and effectiveness of the new ECL labels, compared with 32P, for nucleic acid probe applications. We describe formats involving conventional methodologies and a new format that requires no wash step, allowing simple and rapid sample analysis. These rapid assays also reduce PCR contamination, by requiring less sample handling. Improvements in ECL detectability are currently under investigation for use in DNA probe assays without amplification.

APA, Harvard, Vancouver, ISO, and other styles

22

Shi, Lihong, Xiaoqing Liu, Haijuan Li, and Guobao Xu. "Determination of Total Calcium in Plasma by Flow Injection Analysis with Tris(2,2′-bipyridyl)ruthenium(II) Electrochemiluminescent Detection." Electroanalysis 18, no. 16 (August 2006): 1584–89. http://dx.doi.org/10.1002/elan.200603555.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Chun, Kelly, and Jane Yang. "P108 Serum Vedolizumab and Anti-Vedolizumab Antibody: Analysis of 6500 Patient Results Using Lab Developed Electrochemiluminescent Immunoassays (ECLIA)." American Journal of Gastroenterology 114, no. 1 (December 2019): S28. http://dx.doi.org/10.14309/01.ajg.0000613400.90981.a1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Chi, Yuwu, Jianping Duan, Shudan Lin, and Guonan Chen. "Flow Injection Analysis System Equipped with a Newly Designed Electrochemiluminescent Detector and Its Application for Detection of 2-Thiouracil." Analytical Chemistry 78, no. 5 (March 2006): 1568–73. http://dx.doi.org/10.1021/ac051508t.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Yang, Jane, and Kelly Chun. "P020 Serum Ustekinumab and Anti-Ustekinumab Antibody: Analysis of Over 2000 Patient Results Using Lab Developed Electrochemiluminescent Immunoassays (ECLIA)." American Journal of Gastroenterology 114, no. 1 (December 2019): S6. http://dx.doi.org/10.14309/01.ajg.0000613048.42973.3b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Wang, Haijun, Yuhang Song, Yaqin Chai, and Ruo Yuan. "High-sensitive electrochemiluminescent analysis based on co-reactive high-molecular polymer and dual catalysis to generate oxygen in situ." Analytica Chimica Acta 1081 (November 2019): 65–71. http://dx.doi.org/10.1016/j.aca.2019.07.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Tetali, Suryakumari, Eun Mi Lee, Mark H. Kaplan, Joseph W. Romano, and Christine C. Ginocchio. "Chemokine Receptor CCR5 Δ32 Genetic Analysis Using Multiple Specimen Types and the NucliSens Basic Kit." Clinical Diagnostic Laboratory Immunology 8, no. 5 (September 1, 2001): 965–71. http://dx.doi.org/10.1128/cdli.8.5.965-971.2001.

Full text

Abstract:

ABSTRACT Resistance to HIV-1 infection and delayed disease progression have been associated with a 32-bp deletion (Δ32) in the gene encoding the CCR5 chemokine receptor. In the present study we describe the modification of a nucleic acid sequence-based amplification (NASBA)-based CCR5 genotyping assay for a NucliSens Basic Kit (Organon Teknika, Durham, N.C.) format using a new target-specific sandwich oligonucleotide detection methodology. The new method permitted the use of generic electrochemiluminescent probes supplied in the NucliSens Basic Kit, whereas the original NASBA method required expensive target-specific ruthenium detection probes. The Basic Kit CCR5 Δ32 genotypic analysis was in 100% concordance with both the original NASBA assay and DNA PCR results. This study also evaluated the use of multiple specimen types, including peripheral blood mononuclear cells (PBMC), whole blood, dried blood spots, buccal scrapings, and plasma, for CCR5 genotype analysis. The sensitivities of the three assays were comparable when PBMC or whole blood was the specimen source. In contrast, when dried blood spots, buccal scrapings, or plasma was used as the sample source, the sensitivity of DNA PCR was 80.95, 42.8, or 0%, respectively, compared to 100% sensitivity obtained with the original NASBA and Basic Kit NASBA assays. Our study indicates that the NucliSens Basic Kit NASBA assay is very sensitive and specific for CCR5 Δ32 genotyping using multiple sample types.

APA, Harvard, Vancouver, ISO, and other styles

28

ZHOU, X., D. XING, D. ZHU, Y. TANG, and L. JIA. "Development and application of a capillary electrophoresis–electrochemiluminescent method for the analysis of enrofloxacin and its metabolite ciprofloxacin in milk." Talanta 75, no. 5 (June 15, 2008): 1300–1306. http://dx.doi.org/10.1016/j.talanta.2008.01.040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Wang, Haijun, Yaqin Chai, Hang Li, and Ruo Yuan. "Sensitive electrochemiluminescent immunosensor for diabetic nephropathy analysis based on tris(bipyridine) ruthenium(II) derivative with binary intramolecular self-catalyzed property." Biosensors and Bioelectronics 100 (February 2018): 35–40. http://dx.doi.org/10.1016/j.bios.2017.08.054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Long, Dongping, Yunfei Shang, Youyi Qiu, Bin Zhou, and Peihui Yang. "A single-cell analysis platform for electrochemiluminescent detection of platelets adhesion to endothelial cells based on Au@DL-ZnCQDs nanoprobes." Biosensors and Bioelectronics 102 (April 2018): 553–59. http://dx.doi.org/10.1016/j.bios.2017.11.058.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Duan, Yu, Yang Song, Ningke Fan, Yanzhen Yao, Shixiong Deng, Shijia Ding, Bo Shen, and Qiufang Yin. "Self-enhanced luminol-based electrochemiluminescent hydrogels: An ultrasensitive biosensing platform for fusion gene analysis coupled with target-initiated DNAzyme motor." Biosensors and Bioelectronics 197 (February 2022): 113784. http://dx.doi.org/10.1016/j.bios.2021.113784.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Liu, Chao, Xiuhua Wei, and Yifeng Tu. "Development of a reagentless electrochemiluminescent electrode for flow injection analysis using copolymerised luminol/aniline on nano-TiO2 functionalised indium-tin oxide glass." Talanta 111 (July 2013): 156–62. http://dx.doi.org/10.1016/j.talanta.2013.02.068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Kenten, J. H., S. Gudibande, J. Link, J. J. Willey, B. Curfman, E. O. Major, and R. J. Massey. "Improved Electrochemiluminescent Label for DNA Probe Assays: Rapid Quantitative Assays of HIV-1 Polymerase Chain Reaction Products." Clinical Chemistry 38, no. 6 (June 1, 1992): 873–79. http://dx.doi.org/10.1093/clinchem/38.6.873.

Full text

Abstract:

Abstract We describe the characterization and utility of a new electrochemiluminescent (ECL) label for oligonucleotides, utilizing phosphoramidite chemistry. This phosphoramidite of the tris(2,2-bipyridine)ruthenium(II) complex, bis(2,2-bipyridine)(4-[4-(2-cyanoethoxy-N,N-diisopropyl-amino) phosphinoxybutyl]4'-methyl)2,2-bipyridine ruthenium(II) dihexafluorophosphate or Origen phosphoramidite, enables the direct incorporation of the label during automated DNA synthesis. Efficiency of this automated synthesis allows the direct utilization of probes without further purification. Introduction of this labeling group is reproducible, and the ECL signal recovered is not influenced by hybridization. Furthermore, neither hybridization kinetics nor hybrid stability was affected by our label. We also demonstrate the utility of these labels for the development of rapid assays with oligonucleotides direct from automated synthesis. The clinical utility of these labeled oligonucleotides is shown with assays of total nucleic acid, extracted from peripheral blood lymphocytes of patients with acquired immunodeficiency syndrome (AIDS), to detect the human immunodeficiency virus (HIV-1). The results demonstrate the ability of the assay to quantify 30-2000 copies of HIV1 gag genes and to rapidly detect (less than 45 min) HIV-1 gag genes in a nonseparation assay. The application of this assay to clinical samples demonstrates the utility of these assays for rapid and quantitative analysis.

APA, Harvard, Vancouver, ISO, and other styles

34

Rosser, Charles Joel, Yoshiko Shimizu, Hideki Furuya, Peter Bryant-Greenwood, Owen Chan, Yunfeng Dai, Mark Thornquist, and Steve Goodison. "A multiplex immunoassay for the non-invasive detection of bladder cancer." Journal of Clinical Oncology 34, no. 2_suppl (January 10, 2016): 471. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.471.

Full text

Abstract:

471 Background: Urine based assays that can non-invasively detect bladder cancer (BCa) have the potential to reduce unnecessary and invasive procedures. The purpose of this study was to develop a multiplex immunoassay that can accurately and simultaneously monitor 10 diagnostic urinary protein biomarkers for application as a non-invasive test for BCa detection Methods: A custom electrochemiluminescent (ECL) multiplex assay was constructed (Meso Scale Diagnostics, LLC, Rockville, MD) to detect the following urinary proteins; IL8, MMP9, MMP10, ANG, APOE, SDC1, A1AT, PAI1, CA9 and VEGFA. Voided urine samples from two cohorts (cohort #1 n = 62 and cohort #2 n = 200) were collected prior to cystoscopy and samples were analyzed blinded to the clinical status of the participants. Means (±SD) and receiver operating characteristic (ROC) curve analysis were used to compare assay performance and to assess the diagnostic accuracy of the diagnostic signature. Results: Comparative diagnostic performance analyses revealed an AUROC value of 0.9258 for the multiplex assay and 0.9467 for the combination of the single-target ELISA assays (p = 0.625), so there was no loss of diagnostic utility for the MSD multiplex assay. Analysis of the independent 200-sample cohort using the multiplex assay achieved an overall diagnostic sensitivity of 0.85, specificity of 0.81, positive predictive value 0.82 and negative predictive value 0.84. Conclusions: It is technically feasible to simultaneously monitor complex urinary diagnostic signatures in a single assay without loss of performance. The described protein-based assay has the potential to be developed for the non-invasive detection of BCa.

APA, Harvard, Vancouver, ISO, and other styles

35

Jiang, Wencan, Gongwei Sun, Wenbin Cui, Shasha Men, Miao Jing, Danna Pu, Sichun Zhang, Xiaozhou Yuan, Xinrong Zhang, and Chengbin Wang. "Evaluation of an Element-Tagged Duplex Immunoassay Coupled with Inductively Coupled Plasma Mass Spectrometry Detection: A Further Study for the Application of the New Assay in Clinical Laboratory." Molecules 25, no. 22 (November 17, 2020): 5370. http://dx.doi.org/10.3390/molecules25225370.

Full text

Abstract:

Background: Element-tagged immunoassay coupled with inductively coupled plasma mass spectrometry (ICP-MS) detection has the potential to revolutionize immunoassay analysis for multiplex detection. However, a further study referring to the standard evaluation and clinical sample verification is needed to ensure its reliability for simultaneous analysis in clinical laboratories. Methods: Carcinoembryonic antigen (CEA) and α-fetoprotein (AFP) were chosen for the duplex immunoassay. The performance of the assay was evaluated according to guidelines from the Clinical and Laboratory Standards Institute (CLSI). Moreover, reference intervals (RIs) of CEA and AFP were established. At last, 329 clinical samples were analyzed by the proposed method and results were compared with those obtained with electrochemiluminescent immunoassay (ECLIA) method. Results: The measurement range of the assay was 2–940 ng/mL for CEA and 1.5–1000 ng/mL for AFP, with a detection limit of 0.94 ng/mL and 0.34 ng/mL, respectively. The inter-assay and intra-assay imprecision were all less than 6.58% and 10.62%, respectively. The RI of CEA and AFP was 0–3.84 ng/mL and 0–9.94 ng/mL, respectively. Regarding to clinical sample detection, no significant difference was observed between the proposed duplex assay and the ECLIA method. Conclusions: The ICP-MS-based duplex immunoassay was successfully developed and the analytical performance fully proved clinical applicability. Well, this could be different with other analytes.

APA, Harvard, Vancouver, ISO, and other styles

36

Shelton, Daniel R., and Jeffrey S. Karns. "Quantitative Detection of Escherichia coli O157 in Surface Waters by Using Immunomagnetic Electrochemiluminescence." Applied and Environmental Microbiology 67, no. 7 (July 1, 2001): 2908–15. http://dx.doi.org/10.1128/aem.67.7.2908-2915.2001.

Full text

Abstract:

ABSTRACT A protocol for the quantitative detection of Escherichia coli O157 in raw and concentrated surface waters using immunomagnetic electrochemiluminescence (IM-ECL) was developed and optimized. Three antibody sandwich formats were tested: commercial anti-O157:H7 IM beads, IM beads made in-house with a polyclonal anti-O157:H7 immunoglobulin G (IgG), or IM beads made in-house with a monoclonal anti-O157:H7 IgG coupled with a polyclonal anti-O157:H7 IgG to which an electrochemiluminescent label (TAG) was attached. The monoclonal IM bead-polyclonal TAG format was chosen for optimization because it gave lower background levels and linear regression slopes of ca. 1.0, indicative of a constant ECL signal per cell. The dynamic range was ca. 101 to 105 cells ml−1 in phosphate-buffered saline and in raw water samples. The monoclonal IM beads selectively captured E. coli O157 cells in the presence of ca. 108 cells of a non-O157 strain of E. coli ml−1. Background ECL signals from concentrated (100-fold) water samples were substantially higher and more variable than raw water samples. The background signal was partially eliminated by the addition of polyvinylpolypyrrolidone. Successive cell capture incubations, termed sequential bead capture (SBC), were optimized for establishing baseline ECL values for individual water samples. The linear dynamic range with SBC was ca. 102 to 105 E. coli O157 cells ml of concentrated water−1. To validate the protocol, 10-liter surface water samples were spiked with ca. 5,000E. coli O157 (Odwalla) cells and concentrated by vortex filtration, and 1- or 3-ml aliquots were analyzed by IM-ECL. Differential ECL signals (SBC) from 1- and 3-ml samples were statistically significant and were generally consistent with standard curves for these cell concentrations. Enrichments were conducted with aliquots of spiked raw water and concentrated water using EC broth and minimal lactose broth (MLB). All tubes with concentrated water became turbid and gave a positive ECL response for E. coli O157 (>10,000 ECL units); MLB gave a somewhat higher detection rate with spiked raw water. The potential sensitivity of the IM-ECL assay is ca. 25 E. coli O157 cells ml of raw water−1, 25 cells 100 ml of 100-fold concentrated water−1, or 1 to 2 viable cells liter−1 with concentration and enrichment. The IM-ECL assay appears suitable for routine analysis and screening of water samples.

APA, Harvard, Vancouver, ISO, and other styles

37

Abaturov, Aleksandr, and Anna Nikulina. "Genotype C/C 13910 of the Lactase Gene as a Risk Factor for the Formation of Insulin-Resistant Obesity in Children." Acta Medica (Hradec Kralove, Czech Republic) 62, no. 4 (2019): 150–55. http://dx.doi.org/10.14712/18059694.2020.4.

Full text

Abstract:

Introduction: To reduce the risk of insulin resistance in obesity in children with lactase gene genotypes, we studied the factors that stimulate the chronic inflammatory process. Material and methods: 109 children 6–18 years of age were investigated. The main group (n = 56) was presented by children with signs of insulin-resistant obesity according to the criteria of the European Society of Endocrinology and the Pediatric Endocrine Society. The control group (n = 53) included obese children without insulin resistance. A comprehensive clinical examination, food diary analysis, genotyping of the lactase gene by means of the polymerase chain reaction, the Immunochemical Test Method with Electrochemiluminescent Detection of basal insulinemia, Hydrogen breath test with lactose load, sequential analysis, ROC analysis were carried out. Results: Clinical manifestations of lactose maldigestion in a child increased the risk of possible insulin resistance (prognostic coefficient (PC +2.6), as well as the presence of the lactase C/C 13910 gene genotype (PC +5.8) did. The genotype C/T 13910 in children had a protective effect on the risk of obesity (PC −2.9). The lowest risk of insulin-resistant obesity in observed among children with the genotype T/T 13910 (PC −12). Conclusion: The presence of the C/C 13910 genotype of the lactase gene is the main factor formation of insulin resistance in children’s obesity. What is known? The genotype C/C 13910 of the lactase gene as a risk factor for the chronic inflammatory process in the body. What is New? Genotype C/C 13910 of the lactase gene as a risk factor for insulin-resistant obesity in children.

APA, Harvard, Vancouver, ISO, and other styles

38

Jiang, Nan, Tian Tian, Xianyang Chen, Guofen Zhang, Lijie Pan, Chengping Yan, Guoshan Yang, Lili Wang, Xuchen Cao, and Xin Wang. "A Diagnostic Analysis Workflow to Optimal Multiple Tumor Markers to Predict the Nonmetastatic Breast Cancer from Breast Lumps." Journal of Oncology 2021 (July 8, 2021): 1–10. http://dx.doi.org/10.1155/2021/5579373.

Full text

Abstract:

Objective. To assess the diagnostic performance of clinically common single markers and combinations to distinguish nonmetastatic breast cancer and benign breast tumor. A predictive model with a better diagnostic ability for nonmetastatic breast cancer was established by using the diagnostic process. Methods. A total of 222 patients with nonmetastatic breast cancer and 265 patients with benign breast disease were enrolled in this study. CEA, Ca 15-3, Ca 125, Ca 72-4, CYFRA 21-1, FERR, AFP, and NSE were measured by an electrochemiluminescent immunoenzymometric assay on the Elecsys system. There are four key steps for our diagnostic workflow, that is, feature selection, algorithm selection, parameter optimization, and outer test data was used to validate the optimal algorithm and markers. Results. CEA, Ca 15-3, CYFRA 21-1, AFP, and FERR were selected using the t-test in our inner development set. The optimal algorithm among logical regression, decision tree, support vector machine, random forest, and gradient boost machine was selected by 10-fold cross-validation, and we found that random forest and logistic regression are the better classification. The outer test data was used to validate the best markers and classification. The random forest with CEA, Ca 15-3, CYFRA 21-1, AFP, and FERR showed the optimal combination for distinguishing breast cancer and benign breast disease. The AUC value was 0.888, the cut-off point was 0.484, and sensitivity and specificity were 78.9% and 90.1%. Conclusions. No single marker of these eight markers was good at identifying nonmetastatic breast cancer from benign tumors. But a diagnostic analysis workflow was established to develop a predictive model with better diagnostic capability for nonmetastatic breast cancer. This workflow is also applicable to the optimization of other disease markers and diagnostic models. The predictive model showed good diagnostic performance, and it could be gradually incorporated as a support method for the diagnosis of nonmetastatic breast cancer.

APA, Harvard, Vancouver, ISO, and other styles

39

Susianto, Susianto. "EFEK FORTIFIKASI VITAMIN B12 TERHADAP KADAR VITAMIN B12 SERUM DAN HOMOSISTEIN SERUM PADA VEGETARIAN." Jurnal Ilmu Kesehatan Bhakti Husada: Health Sciences Journal 11, no. 1 (June 29, 2020): 114–20. http://dx.doi.org/10.34305/jikbh.v11i1.150.

Full text

Abstract:

Introduction: Vegetarians consume plant-based foods with or without eggs and milk. Vegetarians are at risk of vitamin B12 deficiency, as natural sources of vitamin B12 are limited to animal-based foods. Vitamin B12 deficiency can lead to megaloblastic anemia, nerve damage and increase homocysteine level. Higher homocysteine level can increase the risk of coronary heart disease and stroke. The objective of this study was to investigate the effect of vitamin B12 fortification on the level of serum vitamin B12 and homocysteine in vegetarian. Method: The research design was an experimental study, community trial. The samples were 42 vegetarians with vitamin B12 deficiency (< 156 pmol/L) selected from 118 vegetarians as members of Indonesia Vegetarian Society (IVS) Pekanbaru, treated by vitamin B12 fortified oatmeal for three months from March to June 2010. Serum vitamin B12 and homocysteine were measured by electrochemiluminescent immunoassay and microparticle enzyme immunoassay method respectively. Result: Prevalence of vitamin B12 deficiency in vegetarian was 35.6%. Statistical analysis showed a significant increase of serum vitamin B12 from 124.6 to 284.6 pmol/L (p=0.001) and significant decrease of serum homocysteine from 20.1 to 15.1 µmol/L (p=0.001). Conclusion: Consumption of vitamin B12 fortified oatmeal increases the level of serum vitamin B12 and decreases the level of serum homocysteine significantly in vegetarian with vitamin B12 deficiency.

APA, Harvard, Vancouver, ISO, and other styles

40

Jiang, Wencan, Gongwei Sun, Xinyu Wen, Shasha Men, Wenbin Cui, Miao Jing, Xingwang Jia, et al. "Development and evaluation of an element-tagged immunoassay coupled with inductively coupled plasma mass spectrometry detection: can we apply the new assay in the clinical laboratory?" Clinical Chemistry and Laboratory Medicine (CCLM) 58, no. 6 (June 25, 2020): 873–82. http://dx.doi.org/10.1515/cclm-2019-0566.

Full text

Abstract:

AbstractIntroductionElement-tagged immunoassay coupled with inductively coupled plasma-mass spectrometry (ICP-MS) detection has the potential to revolutionize immunoassay analysis in clinical detection; however, a systematic evaluation with the standard guidelines of the assay is needed to ensure its performance meets the requirements of the clinical laboratory.MethodsCarcinoembryonic antigen (CEA) was chosen for analysis using the proposed method. A systematic evaluation of the proposed assay was carried out according to the Clinical and Laboratory Standards Institute (CLSI). The 469 clinical samples were analyzed using the new method and compared with the electrochemiluminescent immunoassay (ECLIA) method.ResultsThe measurement range of the assay was 1–900 ng/mL, with a detection limit of 0.83 ng/mL. The inter-assay and intra-assay imprecision were 4.67% and 5.38% with high concentration samples, and 9.27% and 17.64% with low concentration samples, respectively. The cross-reactivity (%) for different antigens was less than 0.05%, and the recovery was between 94% and 108%. Percentage deviation of all the dilutions was less than 12.5% during linearity estimation. The interference bias caused by different substances was less than 10%. The reference interval of the assay was 0–4.442 ng/mL. Comparison with the commercial ECLIA method for clinical sample detection, the proposed method showed a correlation of 0.9878 and no significant differences between the methods were observed (p = 0.6666).ConclusionsThe ICP-MS based immunoassay was successfully developed, and the analytical performance of the assay met the requirements of the CLSI, which fully proved the clinical transferability and application of the new method.

APA, Harvard, Vancouver, ISO, and other styles

41

Sánchez-Carbayo, Marta, Antonia Espasa, Virtudes Chinchilla, Enrique Herrero, Julián Megías, Antonio Mira, and Federico Soria. "New Electrochemiluminescent Immunoassay for the Determination of CYFRA 21-1: Analytical Evaluation and Clinical Diagnostic Performance in Urine Samples of Patients with Bladder Cancer." Clinical Chemistry 45, no. 11 (November 1, 1999): 1944–53. http://dx.doi.org/10.1093/clinchem/45.11.1944.

Full text

Abstract:

Abstract Background: A new electrochemiluminescent immunoassay (ECLIA) has been developed for the determination of cytokeratin 19 (CYFRA 21-1) in the Elecsys 2010 immunoassay system. Urinary CYFRA 21-1 might have a role in the diagnosis of bladder cancer. Methods: We performed an analytical evaluation of the CYFRA 21-1 ECLIA for serum and urine samples. The clinical value of urinary CYFRA 21-1 for the detection of bladder cancer was evaluated through its measurement in 226 urine samples from symptomatic and asymptomatic controls. Results: At concentrations of 2–30 μg/L, within-assay imprecision (CV) was below 2.1% for sera and 3.3% for urines, with interassay CVs below 3.3% for sera and 4.9% for urines. The day-to-day CV was <20% at concentrations >0.2 μg/L (functional sensitivity). Measurement of diluted samples showed that the assay estimated CYFRA 21-1 between 98% and 103% for sera and 98% and 105% for urines. Recovery of added CYFRA 21-1 was 99–105% for sera and 96–115% for urines. We separately compared serum and urine CYFRA 21-1 ECLIA results with those obtained with an IRMA (CIS bio international). Regression analysis for sera was: CYFRA 21-1 (ECLIA) = 0.520 + 1.018 CYFRA 21-1 (IRMA); [95% confidence interval (CI) (y-intercept), −0.260 to 1.309]; 95% CI (slope), 0.978–1.060; n = 100; Sy|x = 3.242; r2 = 0.987. For urine samples it was: CYFRA 21-1 (ECLIA) = 0.716 + 0.966 CYFRA 21-1 (IRMA); 95% CI (y-intercept), 0.009–1.422; 95% CI (slope), 0.956–0.976; n = 100; Sy|x = 4.136; r2 = 0.986. In urine samples voided by patients with and without bladder cancer, the best ROC analysis discrimination provided 81.0% (95% CI, 72.7–87.7%) sensitivity and 97.2% (95% CI, 90.2–99.6%) specificity at a threshold value of 5.7 μg/L. Conclusions: Our initial evaluation showed reliable analytical performance for urinary CYFRA 21-1, which might assist urologists in the detection of bladder cancer as a noninvasive adjunct to cystoscopy.

APA, Harvard, Vancouver, ISO, and other styles

42

Bilchik, Anton J., Sukamal Saha, David Wiese, James A. Stonecypher, Thomas F. Wood, Stuart Sostrin, Roderick R. Turner, He-Jing Wang, Donald L. Morton, and Dave S. B. Hoon. "Molecular Staging of Early Colon Cancer on the Basis of Sentinel Node Analysis: A Multicenter Phase II Trial." Journal of Clinical Oncology 19, no. 4 (February 15, 2001): 1128–36. http://dx.doi.org/10.1200/jco.2001.19.4.1128.

Full text

Abstract:

PURPOSE: Approximately 30% of patients with American Joint Committee on Cancer stage I or II colorectal cancer (CRC) develop systemic disease. We hypothesized that multimarker reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of sentinel lymph nodes (SNs) draining a primary CRC could detect micrometastases not detected by conventional histopathologic analysis. PATIENTS AND METHODS: In a multi-institutional study, 40 patients with primary CRC underwent dye-directed lymphatic mapping at the time of colon resection. Each dye-stained SN was tagged, and the tumor and regional nodes were resected en bloc. All lymph nodes were examined by conventional hematoxylin and eosin (HE) staining. In addition, each SN was cut into multiple sections for cytokeratin immunohistochemical (CK-IHC) staining and for RT-PCR and electrochemiluminescent detection of three markers: β-chain human chorionic gonadotropin, hepatocyte growth factor receptor, and universal melanoma-associated antigen. Whenever possible, RT-PCR assay was also performed on primary tumor tissue. The detection sensitivity of individual markers was 10−3 to 10−4 μg of RNA and one to five tumor cells in 107 lymphocytes of healthy donors. RESULTS: One to three SNs were identified in each patient. An average of 15 nodes were removed from each CRC specimen. No nonsentinel (untagged) node contained evidence of tumor if all tagged (sentinel) nodes in the same specimen were histopathology tumor-negative. HE staining of SNs identified tumor in 10 patients (25%), and CK-IHC of SNs identified occult micrometastases in four patients (10%) whose SNs were negative by HE. Of the remaining 26 patients with no evidence of SN involvement by HE or CK-IHC, 12 (46%) had positive RT-PCR results. The number of markers expressed in each SN correlated (P < .04) with the T stage of the primary tumor. There was 79% concordance in marker expression for the respective pairs (n = 38) of primary tumor and histopathologically positive SNs, and 86% (12 of 14) concordance between RT-PCR positive and histopathologically positive SNs. CONCLUSION: Identification and focused examination of the SN is a novel method of staging CRC. CK-IHC and RT-PCR identified occult micrometastases in 53% of patients whose SNs were negative by conventional staging techniques. These ultrasensitive assays of the SN can identify patients who may be at high risk for recurrence of CRC and therefore are more likely to benefit from systemic adjuvant therapy.

APA, Harvard, Vancouver, ISO, and other styles

43

Maksymowych, Walter P., Gilles Boire, Dirkjan van Schaardenburg, Stephanie Wichuk, Samina Turk, Maarten Boers, Katherine A. Siminovitch, et al. "14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis." Journal of Rheumatology 42, no. 9 (July 15, 2015): 1587–94. http://dx.doi.org/10.3899/jrheum.141385.

Full text

Abstract:

Objective.To describe the expression and diagnostic use of 14-3-3η autoantibodies in early rheumatoid arthritis (RA).Methods.14-3-3η autoantibody levels were measured using an electrochemiluminescent multiplexed assay in 500 subjects (114 disease-modifying antirheumatic drug-naive patients with early RA, 135 with established RA, 55 healthy, 70 autoimmune, and 126 other non-RA arthropathy controls). 14-3-3η protein levels were determined in an earlier analysis. Two-tailed Student t tests and Mann-Whitney U tests compared differences among groups. Receiver-operator characteristic (ROC) curves were generated and diagnostic performance was estimated by area under the curve (AUC), as well as specificity, sensitivity, and likelihood ratios (LR) for optimal cutoffs.Results.Median serum 14-3-3η autoantibody concentrations were significantly higher (p < 0.0001) in patients with early RA (525 U/ml) when compared with healthy controls (235 U/ml), disease controls (274 U/ml), autoimmune disease controls (274 U/ml), patients with osteoarthritis (259 U/ml), and all controls (265 U/ml). ROC curve analysis comparing early RA with healthy controls demonstrated a significant (p < 0.0001) AUC of 0.90 (95% CI 0.85–0.95). At an optimal cutoff of ≥ 380 U/ml, the ROC curve yielded a sensitivity of 73%, a specificity of 91%, and a positive LR of 8.0. Adding 14-3-3η autoantibodies to 14-3-3η protein positivity enhanced the identification of patients with early RA from 59% to 90%; addition of 14-3-3η autoantibodies to anticitrullinated protein antibodies (ACPA) and/or rheumatoid factor (RF) increased identification from 72% to 92%. Seventy-two percent of RF- and ACPA-seronegative patients were positive for 14-3-3η autoantibodies.Conclusion.14-3-3η autoantibodies, alone and in combination with the 14-3-3η protein, RF, and/or ACPA identified most patients with early RA.

APA, Harvard, Vancouver, ISO, and other styles

44

Parlant-Pinet, Lucile, Catherine Harthé, Florence Roucher, Yves Morel, Françoise Borson-Chazot, Gérald Raverot, and Véronique Raverot. "Macroprolactinaemia: a biological diagnostic strategy from the study of 222 patients." European Journal of Endocrinology 172, no. 6 (June 2015): 687–95. http://dx.doi.org/10.1530/eje-14-1073.

Full text

Abstract:

ObjectivesGel filtration chromatography (GFC), the gold standard for macroprolactinaemia (MPRL) diagnosis, is a slow, costly and labour-intensive method. To limit the number of GFC required, we evaluated two screening tests for MPRL: prolactin (PRL) recovery after polyethylene glycol (PEG) precipitation and PRL concentration ratio, derived from two assays, each having different big-big-PRL cross-reactivities.In some patients, MPRL is characterised by clinical symptoms which can be associated with an excess of monomeric PRL. We compared the monomeric PRL concentration obtained from GFC with the PRL concentration i) on a cobas e 601 analyser and ii) in the supernatant after PEG precipitation.Design and methodsWe studied hyperprolactinaemic sera subjected to physician-ordered GFC, between February 2013 and July 2014. We performed PEG precipitation (to evaluate the PRL concentration and rate of recovery in the supernatant) and two PRL assays: RIA and electrochemiluminescent assay (ECLIA), on a Roche cobas e 601 analyser, and calculated the RIA/ECLIA ratio.ResultsAmong the 222 sera, we were able to diagnose or exclude MPRL in 72.1% of cases, based solely on the ratio and/or recovery. In the remaining cases, GFC was necessary for making a diagnosis. Elevated monomeric PRL was present in 10.9% of macroprolactinaemic sera. In the case of MPRL, both PRL measurements on the cobas analyser and in the supernatant weakly correlated with monomeric PRL values obtained from GFC.ConclusionsThe combination of PEG and RIA/ECLIA ratio analysis reduced the number of necessary GFC. However, GFC is essential in MPRL cases to evaluate the monomeric PRL concentration.

APA, Harvard, Vancouver, ISO, and other styles

45

Qi, Liming, Fan Yuan, and Guobao Xu. "Advances in electrochemiluminescence analysis." SCIENTIA SINICA Chimica 48, no. 8 (July 9, 2018): 914–25. http://dx.doi.org/10.1360/n032018-00053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Li, Lingling, Ying Chen, and Jun-Jie Zhu. "Recent Advances in Electrochemiluminescence Analysis." Analytical Chemistry 89, no. 1 (December 13, 2016): 358–71. http://dx.doi.org/10.1021/acs.analchem.6b04675.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Kempf, Tibor, Anja Guba-Quint, Jarl Torgerson, Maria Chiara Magnone, Carolina Haefliger, Maria Bobadilla, and Kai C. Wollert. "Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial." European Journal of Endocrinology 167, no. 5 (November 2012): 671–78. http://dx.doi.org/10.1530/eje-12-0466.

Full text

Abstract:

Objective Growth differentiation factor-15 (GDF-15) is a stress-responsive cytokine that is increased in obesity and established type 2 diabetes. We assessed whether GDF-15 can predict future insulin resistance and impaired glucose control in obese nondiabetic individuals. Design and methods Plasma GDF-15 concentrations were measured with an automated electrochemiluminescent immunoassay at baseline and after 4 years in 496 obese nondiabetic individuals (52% men, median age 48 years, median body mass index (BMI) 37.6 kg/m2) enrolled in the XENical in the prevention of Diabetes in Obese subjects (XENDOS) trial. Results The median GDF-15 concentration at baseline was 869 ng/l (interquartile range 723–1064 ng/l). GDF-15 was related to body weight, BMI, waist-to-hip ratio, and insulin resistance (homeostasis model assessment of insulin resistance (HOMA-IR)) (all P<0.01). Changes in GDF-15 from baseline to 4 years were related to changes in body weight, BMI, waist-to-hip ratio, and HOMA-IR (all P<0.05). Baseline GDF-15 was associated with the risk to have prediabetes or diabetes at 4 years by univariate analysis (odds ratio (OR) for 1 unit increase in ln GDF-15, 3.2; 95% confidence interval (CI): 1.7–6.1; P<0.001), and after multivariate adjustment for age, gender, treatment allocation (orlistat vs placebo), BMI, waist-to-hip ratio, and glucose control at baseline (OR 2.2; 95% CI: 1.1–4.7; P=0.026). Similarly, baseline GDF-15 was independently associated with HOMA-IR at 4 years (P=0.024). Conclusions This first longitudinal study of GDF-15 in a large cohort of obese individuals indicates that GDF-15 is related to abdominal obesity and insulin resistance and independently associated with future insulin resistance and abnormal glucose control.

APA, Harvard, Vancouver, ISO, and other styles

48

Bian, Jing, Xiaoxu Sun, Bo Li, and Liang Ming. "Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients With Endometrial Cancer." Technology in Cancer Research & Treatment 16, no. 4 (August 24, 2016): 435–39. http://dx.doi.org/10.1177/1533034616666644.

Full text

Abstract:

Purpose: Serum markers with increased sensitivity and specificity for endometrial cancer are required. To date, no good marker has met this standard. The aims of our study were to evaluate the utility of tumor markers HE4, CA125, CA724, and CA19-9 as potential markers in patients diagnosed with endometrial cancer. Methods: Blood samples from 105 patients with endometrial cancer and 87 healthy women were analyzed by Roche electrochemiluminescent immunoassay, and serum values were measured for the following biomarkers: HE4, CA125, CA724, and CA19-9. Results: Serum HE4, CA125, CA724, and CA19-9 concentrations were significantly higher in patients with endometrial cancer, compared with controls ( P < .001). In the receiver operating characteristic analysis, the area under the curve value for combination of HE4, CA125, CA724, and CA19-9 was 82.1% (95% confidence interval: 75.3%-86.2%), the maximum area of the test groups. For all stages of patients with endometrial cancer, HE4 had higher sensitivity (58%), positive predictive value (60%), and negative predictive value (67%) than any other single tumor marker, and in the combination of HE4, CA125, CA724, and CA19-9, the sensitivity and positive predictive values reached 59.1% and 88%, respectively. Meanwhile, the receiver operating characteristic area under the curve of the combination of the 4 markers was significantly increased than any other group, either in stage I or in stage II to IV cases. HE4 and CA125 both correlate with advanced age; in addition, HE4 was related to pathology subtypes and positive adnexal involvement, CA125 was related to International Federation of Gynecology and Obstetrics stage, CA19-9 was related to International Federation of Gynecology and Obstetrics stage, and CA724 was correlated with positive lymph node. Conclusion: Combination of HE4, CA125, CA724, and CA19-9 has the highest value in diagnosing endometrial cancer, and they can be a useful tissue immune marker for patients with endometrial cancer.

APA, Harvard, Vancouver, ISO, and other styles

49

LI, Su-Ping, Huai-Min GUAN, Guo-Bao XU, and Yue-Jin TONG. "Progress in Molecular Imprinting Electrochemiluminescence Analysis." Chinese Journal of Analytical Chemistry 43, no. 2 (February 2015): 294–99. http://dx.doi.org/10.1016/s1872-2040(15)60805-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Zhang, Qian, Xin Zhang, and Qiang Ma. "Recent Advances in Visual Electrochemiluminescence Analysis." Journal of Analysis and Testing 4, no. 2 (April 2020): 92–106. http://dx.doi.org/10.1007/s41664-020-00129-w.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!